Daxxify® Named Time’s Best Invention
Daxxify® has become the first facial injectable to be named to TIME’s Best Inventions of 2023, signalling a significant advancement in the field of neuromodulator treatments. This annual list, published by TIME magazine, showcases innovations across various sectors, including artificial intelligence, green energy, and more, highlighting the innovations that have a meaningful impact on our lives.
Made exclusively in the US, Daxxify is an FDA-approved treatment aimed at improving moderate to severe frown lines in adults. What sets it apart from traditional neuromodulators, such as BOTOX, is its long-lasting effects, a quality that nearly 90% of patients and physicians have expressed a need for. As a result, it’s making inroads into the U.S. neuromodulator market, currently valued at $2.5 billion.
The efficacy and safety profile of Daxxify is backed by more than 20 years of research and development and the largest U.S. Phase 3 clinical program ever conducted for glabellar lines. Daxxify’s differentiated performance profile is achieved through its unique formulation, powered by Revance’s proprietary Peptide Exchange Technology™, a stabilizing peptide excipient which does not require human or animal-based components. Further, in a recent independent survey, Daxxify injectors revealed that the product has additional benefits extending beyond duration, including fast onset of treatment effect and the appearance of improved skin smoothness.
“We are honored to be recognized by TIME® and are encouraged by the expanding impact of Daxxify in the aesthetics space,” said Mark Foley, Chief Executive Officer. “By leveraging research in the emerging field of peptide technology and after evaluating a number of peptide sequences, Revance developed an injectable formulation that doesn’t require animal or human components to stabilize the toxin like competitor products. Daxxify has demonstrated the ability to deliver high patient satisfaction stemming from long-lasting results, fast onset and the appearance of improved skin texture*, providing the first true innovation in neuromodulator product formulation in over 30 years. The aesthetic facial injectables market is robust and growing and we are very pleased to be setting the new standard with Daxxify.”